Meta-analysis reveals metformin significantly reduces myocardial hypertrophy in patients, suggesting it may support cardiovascular health benefits.
Our data demonstrated that metformin administration results in a modest but significant effect in reducing LVMI, particularly over longer treatment durations and in non-diabetic individuals. However, its impact on other echocardiographic parameters remains uncertain. Despite the need for further research (experimental and clinical), our study supports metformin as a therapeutic strategy for optimizing cardiovascular benefits in diabetic and non-diabetic patients at risk of cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Shaker et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: